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Abstract
Background: We reported that roflumilast, a phosphodiesterase 4 inhibitor, given orally at 5 mg/
kg to mice prevented the development of emphysema in a chronic model of cigarette smoke
exposure, while at 1 mg/kg was ineffective. Here we investigated the effects of roflumilast on the
volume density (VV) of the inflammatory cells present in the lungs after chronic cigarette smoke
exposure.
Methods:  Slides were obtained from blocks of the previous study and VV  was assessed
immunohistochemically and by point counting using a grid with 48 points, a 20× objective and a
computer screen for a final magnification of 580×. Neutrophils were marked with myeloperoxidase
antibody, macrophages with Mac-3, dendritic cells with fascin, B-lymphocytes with B220, CD4+ T-
cells with CD4+ antibody, and CD8+T-cells with CD8-α. The significance of the differences was
calculated using one-way analysis of variance.
Results: Chronic smoke exposure increased neutrophil VV by 97%, macrophage by 107%, dendritic
cell by 217%, B-lymphocyte by 436%, CD4+ by 524%, and CD8+ by 417%. The higher dose of
roflumilast prevented the increase in neutrophil VV by 78%, macrophage by 82%, dendritic cell by
48%, B-lymphocyte by 100%, CD4+ by 98% and CD8+ VV by 88%. The lower dose of roflumilast
did not prevent the increase in neutrophil, macrophage and B-cell VV but prevented dendritic cells
by 42%, CD4+ by 55%, and CD8+ by 91%.
Conclusion: These results indicate (i) chronic exposure to cigarette smoke in mice results in a
significant recruitment into the lung of inflammatory cells of both the innate and adaptive immune
system; (ii) roflumilast at the higher dose exerts a protective effect against the recruitment of all
these cells and at the lower dose against the recruitment of dendritic cells and T-lymphocytes; (iii)
these findings underline the role of innate immunity in the development of pulmonary emphysema
and (iiii) support previous results indicating that the inflammatory cells of the adaptive immune
system do not play a central role in the development of cigarette smoke induced emphysema in
mice.
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Background
Recently, chronic obstructive pulmonary disease (COPD)
has been defined by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) as a disease character-
ized by progressive, not fully reversible, flow limitation
and "associated with an abnormal inflammatory response
of the lungs to noxious particles and gases" [1]. Thus, a
central role has been attributed to the chronic inflamma-
tory response that in humans is present throughout the
airways and parenchyma and that participates in the pro-
gression and exacerbation of this disease [2].
The attempt to reduce, with the use of anti-inflammatory
agents, lung inflammatory cell infiltration is most appeal-
ing since such an effect would also reduce the lung burden
of both proteases and oxidants. In an approach aiming at
modulating the chronic inflammatory response, corticos-
teroids are used. However, these drugs have been found to
be largely ineffective in attenuating inflammation in
patients with COPD [3]. The resistance to corticosteroids
may involve an impaired activity of the enzyme histone
deacetylase, related to oxidative stress. In fact, a blunted
activity of this enzyme is associated with a reduced
response to corticosteroids and an enhanced expression of
inflammatory cytokines [4].
Thus, as indicated in the GOLD guidelines, there is a
pressing need to develop new agents capable of suppress-
ing the inflammatory response [1]. The phosphodieste-
rases are a large family of intracellular enzymes that
degrade cyclic nucleotides. Among these the phosphodi-
esterase 4 (PDE4) isoenzyme specifically targets 3', 5'-
cyclic adenosine monophosphate (cAMP), a second mes-
senger that exerts inhibitory effects on many inflamma-
tory cells. Neutrophils, macrophages and CD8+ T-
lymphocytes play a significant role in COPD and these
cells have been shown to substantially express PDE4.
Thus, substances that prevent the degradation of cAMP by
inhibiting the activity of PDE4 will enhance the anti-
inflammatory action of this second messenger [5].
In a previous investigation we reported that the specific
PDE4 inhibitor roflumilast, given orally either at 1 mg/kg
or at 5 mg/kg to mice acutely exposed to cigarette smoke,
partially but significantly prevented the smoke-induced
lung neutrophilia.
Additionally, when given orally at the same doses, in a
chronic (7 months) model of cigarette smoke exposure,
the high (5 mg/kg) but not the low dose of roflumilast
completely prevented the smoke-induced development of
emphysema and the drop in desmosine lung content.
Thus, this study showed for the first time that a phos-
phodiesterase 4 inhibitor such as roflumilast, could fully
prevent parenchymal destruction induced by cigarette
smoke [6].
Recent reports indicate that inflammatory cells both of the
innate (macrophages, neutrophils) and adaptive immune
system (B lymphocytes, CD4+ T-lymphocytes, CD8+ T-
lymphocytes) or cells linking innate and adaptive immu-
nity (dendritic cells) may play an important role in the
development of cigarette smoke-induced emphysema [7-
9]. It was thus of interest to investigate the effect of roflu-
milast on the influx into the lung of the inflammatory
cells of the innate and adaptive immune system. This was
done with immunohistochemical methods coupled with
a morphometrical assessment using the paraffin embed-
ded blocks of the previous study.
This investigation could be of help in clarifying the impor-
tance of these cells for the development of cigarette
smoke-induced emphysema. In fact, since the low dose of
roflumilast did not prevent the development of emphy-
sema while the high dose completely blocked it [6], it
would be of interest to analyze the recruitment of inflam-
matory cells under both these conditions.
Methods
In the present investigation the paraffin blocks of a previ-
ous study were used [6]. Briefly, five groups of 2 months
old male mice of the strain C57 Bl/6J were treated as fol-
lows: 1) no treatment/air exposed, 2) roflumilast 5 m/kg
p.o./air exposed, 3) no treatment/smoke exposed, 4) rof-
lumilast 1 mg/kg p.o./smoke exposed, and 5) roflumilast
5 mg/kg p.o./smoke exposed. All animal experiments
were conducted in conformity with the "Guiding Princi-
ples for Research Involving Animals and Human Beings"
and approved by the Local Ethics Committee of the Uni-
versity of Siena.
After chronic exposure to room air or cigarette smoke for
seven months, the animals were sacrificed and the lungs
fixed in formalin (5%) at a pressure of 20 cm H2O. Lung
volume was measured by water displacement. All lungs
were then dehydrated, cleared in toluene and embedded
in paraffin. Tissue sections (7 μm) were pre-treated with
3% hydrogen peroxide to inhibit the activity of the endog-
enous peroxidases. For antigen retrieval, the sections were
heated in a microwave for 20 min in citrate buffer 0.01 M,
pH 6.0, and allowed to cool slowly to room temperature.
The slides were then incubated with 3% bovine serum
albumin for 30 min at room temperature to block non-
specific antibody binding, and then exposed to the fol-
lowing primary antibodies: prediluted rabbit polyclonal
to myeloperoxidase (undiluted) (Abcam, Cambridge,
UK), rat monoclonal anti-mouse MAC-3 (1:20) (BD
Pharmingen, Buccinasco, Italy), rat monoclonal anti-
mouse CD45/B220 (1:20) (BD Pharmingen, Buccinasco,BMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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Italy), rat monoclonal anti-mouse to CD4 (1:1000)
(Abcam, Cambridge, UK), overnight at 4°C.
For myeloperoxidase detection, the tissue sections were
rinsed and incubated with sheep anti-rabbit IgG (1:100)
(Sigma Immuno Chemicals) for 30 min. at room temper-
ature. The staining was revealed by adding peroxidase-
antiperoxidase complex (1:200) (Sigma Immuno Chemi-
cals) prepared from rabbit serum.
For MAC-3, CD4 and CD45R/B220 detection, the sections
were rinsed and incubated with goat polyclonal anti-rat
biotinylated IgG (1:100) (Abcam, Cambridge, UK) for 30
min. at room temperature. The staining was revealed by
adding Streptavidin-horseradish peroxidase (BD
Pharmingen, Buccinasco, Italy).
Detection was accomplished by incubation in diami-
nobenzidine (DAB) freshly dissolved in 0.03% H2O2 in
50 mM Tris/HCl, pH 7.6. As negative controls for the
immunostaining, the primary Ab was replaced by nonim-
munized rabbit or rat serum.
The M.O.M. immunodetection kit (Vector Laboratories,
Burlinghame, CA) was used for both immunodection of
mouse monoclonal to CD8-α (1:100) (Santa Cruz Biotec-
nology Inc, Europe) and to fascin (1:200) (Abcam, Cam-
bridge, UK), a protein highly restricted to dendritic cells
deriving from the different dendritic cell subsets [10]. Fas-
cin is specifically expressed only in mature but not in
immature dendritic cells [11] and its expression is a pre-
requisite for full T-cells activation [12].
The Vector M.O.M. immunodetection kit is designed spe-
cifically to localize mouse primary monoclonal and poly-
clonal antibodies on mouse tissues by using a novel
blocking agent and reducing the undesired background
staining. Immunostaining was revealed by using the
M.O.M. detection kit with DAB substrate.
The volume fractions of the immunopositive cells were
determined by point counting using a grid with 48 points,
a 20× objective and a computer screen for a final magnifi-
cation of 580×. Twenty fields were examined for each pair
of lungs for a total of 960 points. The number of points
that fell on stained cells was divided by the total number
of points on the lung section. This number was then mul-
tiplied by the volume of the lung corrected by the weight
of the mouse to give the total volume of the specifically
stained cells in the lung [13].
The number of animals (N) was 5 in all groups except in
the group "smoke: macrophages" where N = 7;
"smoke+R1: macrophages" where N = 6; and "smoke+R5:
macrophages" where N = 7.
The significance of the differences was calculated using
one-way analysis of variance (ANOVA). A p-value of <
0.05 was considered significant.
Results
Following chronic smoke exposure, the inflammatory
cells of both the innate immune system and of the adap-
tive immune system were significantly increased in the
lung tissue when compared to air exposure.
The neutrophils, which could be observed mainly peri-
bronchially but also in the lung parenchyma (Fig. 1A),
were increased by 97% (p < 0.01, Fig. 1B). Roflumilast, at
the dose 1 mg/kg, did not significantly affect this increase,
while at the dose 5 mg/kg, prevented the increase in neu-
trophil VV by 78% (p < 0.01) (Fig. 1B).
The macrophages, which were observed throughout the
lung parenchyma (Fig. 2A) were increased by 107% (p <
0.01) in comparison to air exposure (Fig. 2B). Roflumi-
last, at the dose 1 mg/kg, did not significantly affect (by
19%) the cigarette smoke-induced increase in macro-
phage VV, but at the dose 5 mg/kg suppressed the increase
in macrophage VV by 82% (p < 0.01) (Fig. 2B). This effect
is slightly more potent of what previously reported [6].
The dendritic cells expressing fascin were increased by
217% (p < 0.01) (Fig. 3B). These cells were found perivas-
cularly (Fig. 3A) in the airway walls and in the paren-
chyma, as well as organized in lymphoid follicles.
Roflumilast, at the dose 1 mg/kg reduced by 42% (p <
0.05) (Fig. 3B) the increase in VV of mature dendritic cells
with the potential ability to activate T-cell proliferation. A
similar effect was obtained with the dose 5 mg/kg (-48%,
p < 0.05) (Fig. 3B).
B-lymphocytes, which were exclusively found organized
in the lymphoid follicles observed both peribronchially
(Fig. 4A) and in the parenchyma, were increased by 436%
(p < 0.01) (Fig. 4B). The low dose of roflumilast potenti-
ated, not significantly, by 26% the increase in B cell VV.
This increase was due to a very high value observed in one
lung of this group and this is reflected by the unusually
high SEM of this group. Roflumilast, at the dose 5 mg/kg,
prevented the increase in B-lymphocyte VV by 100% (p <
0.01) (Fig. 4B).
The CD4+ T-lymphocytes, which were found perivascu-
larly (Fig. 5A), in the airways and in the lymphoid follicles
were increased in the lungs of the mice exposed to ciga-
rette smoke by 524% (p < 0.01) (Fig. 5B). The low dose of
roflumilast reduced the increase in CD4+ cell VV by 55%
(p < 0.05) and the high dose by 98% (p < 0.01) (Fig. 5B).
Following chronic exposure to cigarette smoke CD8+ T-
lymphocytes were visualized perivascularly, peribronchi-BMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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ally, and in lymphoid follicles (Fig. 6A) and were
increased by 417% (p < 0.01) (Fig. 6B). Both doses of rof-
lumilast showed a similar inhibition of the influx of these
cells: 91% at 1 mg/kg and 88% at 5 mg/kg, respectively
(both p < 0.001) (Fig. 6B).
Discussion
The main points of this study are: (i) the effect of chronic
smoke exposure on the recruitment of inflammatory cells
of both the innate and adaptive immune system and (ii)
the effect of the two doses of roflumilast on this recruit-
ment.
With regard to inflammatory cells of the innate immune
system, cigarette smoke exposure resulted in an increase
of approximately 100% of both neutrophil and macro-
phage VV. In particular, neutrophil VV was increased by
97% after 7 months cigarette smoke exposure. This result
A. Immunohistochemical reaction for neutrophil myeloperoxidase on a lung of a C57Bl/6J mouse after a 6 month cigarette  smoke exposure Figure 1
A. Immunohistochemical reaction for neutrophil myeloperoxidase on a lung of a C57Bl/6J mouse after a 6 month cigarette 
smoke exposure. B. Neutrophil volume density in the lung of C57BL76J mice exposed either to room air or to cigarette 
smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = cigarette smoke exposure; R1 = 
treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg po; N = 5 in all groups; * = 
p < 0.01 versus air exposed, ++ = < 0.01 versus smoke exposed. Scale Bar = 40 μm.
A. Immunohistochemical reaction for macrophage Mac-3 on lung parenchyma of a C57Bl/6J mouse after a 6 month cigarette  smoke exposure Figure 2
A. Immunohistochemical reaction for macrophage Mac-3 on lung parenchyma of a C57Bl/6J mouse after a 6 month cigarette 
smoke exposure. B. Macrophage volume density in the lung of C57BL76J mice exposed either to room air or to cigarette 
smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = cigarette smoke exposure; R1 = 
treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg po; N = 5 in all groups 
except "CS -" where N = 7, "CS +R1"where N = 6 and "CS +R5" where N = 7; * = p < 0.01 versus air exposed, ++ = < 0.01 
versus smoke exposed. Scale Bar = 40 μm.BMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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is consistent with the data of a recent report where neu-
trophils, also assessed morphometrically, were increased
by 155% in the lung of C57 Bl/6J mice exposed for one
year to cigarette smoke [14]. A pronounced increase of
neutrophils was found in bronchoalveolar lavage fluids
(BALFs) of mice with the same background and after
exposure to cigarette smoke for 6 months [15,16].
In COPD in man, an increased number of neutrophils is
recovered from sputum and BALFs however, there are rel-
atively small increases of neutrophils in the airways or
parenchyma [17]. The lack of a significant increase in neu-
trophils in the lung parenchyma has been attributed to the
rapid transit that these cells make through the airways and
the lung parenchyma [18]. In our opinion, the discrep-
A. Immunohistochemical reaction for dendritic cell fascin observed perivascularly on a lung of a C57Bl/6J mouse after a 6  month cigarette smoke exposure Figure 3
A. Immunohistochemical reaction for dendritic cell fascin observed perivascularly on a lung of a C57Bl/6J mouse after a 6 
month cigarette smoke exposure. B. Dendritic cell volume density in the lung of C57BL76J mice exposed either to room air or 
to cigarette smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = cigarette smoke 
exposure; R1 = treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg po; N = 5 in 
all groups except "CS +R1"where due to technical problems N = 3; * = p < 0.01 versus air exposed, + = < 0.05 versus smoke 
exposed. Scale Bar = 40 μm.
A. Immunohistochemical reaction for B-lymphocyte CD45/B220 organized in a lymphoid follicle on a lung of a C57Bl/6J mouse  after a 6 month cigarette smoke exposure Figure 4
A. Immunohistochemical reaction for B-lymphocyte CD45/B220 organized in a lymphoid follicle on a lung of a C57Bl/6J mouse 
after a 6 month cigarette smoke exposure. B. B-cell volume density in the lung of C57BL76J mice exposed either to room air 
or to cigarette smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = cigarette smoke 
exposure; R1 = treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg po; N = 5 in 
all groups. * = p < 0.01 versus air exposed, ++ = < 0.01 versus smoke exposed. Scale Bar = 80 μm.BMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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ancy between animal and human data may be explained
by the different methodology used for performing bron-
choalveolar lavage that is known to be representative in
humans of a small region of the lung (segmental lavage).
In the present study, cigarette smoke exposure resulted in
an increase in lung macrophage VV by 107%. Similarly, in
a recent study macrophages were increased by 81% in
mice exposed to cigarette smoke for one year as compared
to air exposed animals [13]. Further, an investigation of
the time course of the increase of inflammatory cells fol-
lowing cigarette smoke exposure revealed a progressive
biphasic increase in BALF macrophages. There was a slight
but significant increase after 7 days, and a marked increase
A. Immunohistochemical reaction for CD4+ T-lymphocyte CD4 seen perivascularly on a lung of a C57Bl/6J mouse after a 6  month cigarette smoke exposure Figure 5
A. Immunohistochemical reaction for CD4+ T-lymphocyte CD4 seen perivascularly on a lung of a C57Bl/6J mouse after a 6 
month cigarette smoke exposure. × 250. B. CD4+ T-cell volume density in the lung of C57BL76J mice exposed either to room 
air or to cigarette smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = cigarette smoke 
exposure; R1 = treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg po; N = 5 in 
all groups. * = p < 0.01 versus air exposed, + = < 0.05 versus smoke exposed, ++ = < 0.01 versus smoke exposed. Scale Bar = 
80 μm.
A. Immunohistochemical reaction for CD8+ T-lymphocyte CD8-α seen organized in a lymphoid follicle on a lung of a C57Bl/6J  mouse after a 6 month cigarette smoke exposure Figure 6
A. Immunohistochemical reaction for CD8+ T-lymphocyte CD8-α seen organized in a lymphoid follicle on a lung of a C57Bl/6J 
mouse after a 6 month cigarette smoke exposure. B. CD8+ T-cell volume density in the lung of C57BL76J mice exposed either 
to room air or to cigarette smoke for 6 months and treated or not with roflumilast at 2 doses. Air = air exposure; CS = ciga-
rette smoke exposure; R1 = treated with roflumilast at the dose 1 mg/kg po; R5 = treated with roflumilast at the dose 5 mg/kg 
po; N = 5 in all groups. * = p < 0.01 versus air exposed, ++ = < 0.01 versus smoke exposed. Scale Bar = 80 μm.BMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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after 6 months. In the lung, the number of macrophages
increased significantly after 12 weeks and remained ele-
vated up to 6 months. [15]. Similarly, in patients with
COPD, there is a marked increase in the number of mac-
rophages both in BALF and in the lung parenchyma [19].
In the present study activated dendritic cells, B-lym-
phocytes and CD4+ and CD8+ T-lymphocytes were also
markedly increased after cigarette smoke. The results of
the dendritic cells are supported by recent data obtained
in the mouse showing a strong increase of dendritic cells
in the lung in response to cigarette smoke [15,20]. The
dendritic cells are antigen presenting cells and the most
likely explanation for the increased number of these cells
could be their recruitment as a response either to smoke
inhalation or to tissue damage. Dendritic cells would then
take up, process and present antigenic substances con-
tained either in cigarette smoke or extracellular matrix
degradation products to T-cells. Additionally, dendritic
cells are not only antigen presenting cells but also follow-
ing cigarette exposure they produce MMP-12 thus, having
the potential for a direct damaging effect [21].
The present results regarding the T-cells are consistent
with the data of a recent work where the total number of
T-lymphocytes was assessed in the lung of mice following
cigarette smoke exposure. At 6 months, total number of
CD4+ T-lymphocytes was increased 2-fold while CD8+ T-
lymphocytes increased by 43%. Additionally, the number
of activated CD4+ and CD8+ T-cells was also found to be
increased [15]. In an attempt to elucidate the role for
CD8+ cells in emphysema, CD8+ T cell-deficient (CD8-/-
) mice were chronically exposed to cigarette smoke. In
contrast to wild-type mice that displayed macrophage,
lymphocyte, and neutrophil recruitment followed by
emphysema, CD8-/- mice had a blunted inflammatory
response and did not develop emphysema. The hypothe-
sis was put forward whereby the CD8+ T-cell product,
IFN-gamma-inducible protein-10, would induce produc-
tion of MMP-12 causing lung destruction and generating
chemotactic factors [22].
In the present study B-lymphocytes, which were found in
peribronchial and parenchymal lymphoid follicles, were
increased by more than 4-fold. Additionally as mentioned
above, mature dendritic cells, CD4+ and CD8+ T-lym-
phocytes were also seen in the lymphoid follicles.
Although CD4 and CD8a are expressed in some mono-
cyte/macrophages or in some KN and dendritic cells, our
findings are consistent with recent data reported in the
mouse after chronic smoke exposure [23]. The formation
of lymphoid follicles defines the appearance of an adap-
tive immune response [24], and the colocalisation of lym-
phocytes and mature dendritic cells in one site suggests
that these cells are functionally communicating [25].
The question that arises is what is the potential role of the
B-cells in the development of emphysema. At present, is
unclear against which antigen this B-cell proliferation
may be directed. The hypothesis of an antigen of micro-
bial nature has been put forward in man [9]. Additionally,
as mentioned above, there are at least two alternative
potential sources that should be considered, cigarette
smoke components and degradation products of extracel-
lular matrix [7]. Another hypothesis suggests that cigarette
smoke, via an oxidative challenge, could modify lung pro-
teins in such a way to make them immunogenic [26].
In COPD patients all these cells of the adaptive immune
system are prominent [27-29] however, their specific role
in the development of the disease is still a matter of dis-
cussion. Similarly, the role of the innate immunity in the
development of cigarette smoke induced emphysema has
not been clarified.
In the present study roflumilast, at the dose of 5 mg/kg
provided a marked and significant protection against the
influx into the lungs of the inflammatory cells of both the
innate and adaptive immune system and this dose of rof-
lumilast has been previously reported to completely pre-
vent the development of emphysema [6]. Thus, the
present results would support a role for all these inflam-
matory cells in the development of emphysema and sug-
gest that inhibition of their recruitment may prevent the
development of the disease.
However, the low dose of roflumilast had no effect on
neutrophil and macrophage VV but prevented the increase
of dendritic cells with the potential to activate T-cell pro-
liferation by 42%, that of CD+4 positive cells by 55% and
almost completely (91%) blocked that of CD8+ positive
cells. This low dose of roflumilast did not have any effect
on the development of emphysema [6].
All these data taken together could be interpreted to sig-
nify that the inflammatory cells of the innate immune sys-
tem are likely to play a major role in the development of
emphysema. This, since their influx is associated with the
presence of this disease and conversely when their recruit-
ment is prevented there is no emphysema (as it is the case
with the dose 5 mg/kg of roflumilast). On the other hand,
the inflammatory cells of the adaptive immune system
probably do not play a major role since emphysema can
fully develop even when the activation of dendritic cells,
and the number of CD4+ and CD8+ positive cells is sig-
nificantly reduced or blocked (as with the dose 1 mg/kg
roflumilast).
This conclusion is consistent with the results of a previous
study performed in SCID mice chronically exposed to cig-
arette smoke. These mice lack functional B- and T-cellsBMC Pulmonary Medicine 2008, 8:17 http://www.biomedcentral.com/1471-2466/8/17
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and peribronchial lymphoid follicles. In these mice ciga-
rette smoke induced a progressive increase of neutrophils
and macrophages in BALF, and induced significant
emphysema. [30].
In a recent work Robbins and co-workers specifically
investigated the impact of chronic tobacco smoke expo-
sure on respiratory immune defence mechanisms [31].
C57Bl/6J mice were chronically exposed to cigarette
smoke and emphysematous lesions were observed after 6
months and were even more pronounced by 10 months.
Cigarette smoke exposure reduced the number and the
maturation of dendritic cells in the lung by altering their
costimulatory molecule expression profile without affect-
ing the CD4+ and CD8+ T-cell compartments. The differ-
ences in dendritic as well as in CD4+ and CD8+ T-cell
profiles observed in different studies dealing with smok-
ing mice may be accounted to the different methodologi-
cal procedures (i.e. manner of smoking, time of exposure,
number or type of cigarette) in use in different labs. All
these data taken together strongly suggest that the cells of
the adaptive immune system do not play a major role in
the development of emphysema in smoking mice. How-
ever, we cannot exclude at the present time a role for adap-
tive immune responses in the progression of
emphysematous lesions induced by cigarette smoking.
Conclusion
In conclusion the results of the present study coupled with
the data of the literature indicate: (i) chronic exposure to
cigarette smoke in mice results in a significant recruitment
into the lung of inflammatory cells of both the innate and
adaptive immune system, as assessed by morphometry;
(ii) roflumilast at the higher dose exerts a protective effect
against the recruitment of all these cells and at the lower
dose against the recruitment of dendritic cells and T-lym-
phocytes; (iii) these findings underline the role of innate
immunity in the development of pulmonary emphysema
and (iiii) support previous results indicating that the
inflammatory cells of the adaptive immune system do not
play a central role in the development of cigarette smoke
induced emphysema in mice.
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